| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 31 | 2025 | 632 | 4.030 |
Why?
|
| Carcinoma, Squamous Cell | 26 | 2025 | 759 | 2.400 |
Why?
|
| Mouth Neoplasms | 4 | 2024 | 98 | 1.820 |
Why?
|
| NF-E2-Related Factor 2 | 6 | 2025 | 131 | 1.400 |
Why?
|
| Receptor, Notch1 | 8 | 2025 | 75 | 1.390 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2025 | 268 | 1.170 |
Why?
|
| Cisplatin | 8 | 2025 | 286 | 0.910 |
Why?
|
| Tumor Suppressor Protein p53 | 10 | 2025 | 739 | 0.900 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2025 | 825 | 0.840 |
Why?
|
| Papillomavirus Infections | 7 | 2024 | 389 | 0.790 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2022 | 25 | 0.770 |
Why?
|
| Lymphatic Metastasis | 1 | 2024 | 433 | 0.770 |
Why?
|
| Cell Line, Tumor | 28 | 2025 | 3673 | 0.760 |
Why?
|
| Glutathione Peroxidase | 1 | 2022 | 48 | 0.750 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2025 | 1989 | 0.740 |
Why?
|
| Mutation | 17 | 2025 | 6177 | 0.720 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2025 | 617 | 0.720 |
Why?
|
| Cell Cycle Proteins | 9 | 2025 | 703 | 0.700 |
Why?
|
| Neovascularization, Pathologic | 4 | 2015 | 234 | 0.680 |
Why?
|
| Signal Transduction | 11 | 2025 | 4683 | 0.640 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 1810 | 0.610 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 130 | 0.610 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2021 | 226 | 0.560 |
Why?
|
| Apoptosis | 13 | 2025 | 1861 | 0.520 |
Why?
|
| DNA Copy Number Variations | 4 | 2020 | 1023 | 0.470 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2025 | 344 | 0.470 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2017 | 36 | 0.430 |
Why?
|
| Tumor Microenvironment | 7 | 2025 | 704 | 0.430 |
Why?
|
| Myeloid Cells | 1 | 2015 | 115 | 0.430 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 111 | 0.420 |
Why?
|
| Thiophenes | 2 | 2017 | 68 | 0.420 |
Why?
|
| Urea | 2 | 2017 | 226 | 0.400 |
Why?
|
| DNA Damage | 5 | 2021 | 527 | 0.380 |
Why?
|
| DNA Methylation | 3 | 2015 | 1086 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2025 | 1001 | 0.380 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1542 | 0.370 |
Why?
|
| Alphapapillomavirus | 2 | 2022 | 46 | 0.350 |
Why?
|
| Protein Kinases | 1 | 2013 | 322 | 0.350 |
Why?
|
| Chemokines, CXC | 2 | 2015 | 36 | 0.330 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 904 | 0.330 |
Why?
|
| Humans | 55 | 2025 | 131680 | 0.330 |
Why?
|
| Cell Proliferation | 13 | 2022 | 2463 | 0.320 |
Why?
|
| Checkpoint Kinase 1 | 4 | 2020 | 29 | 0.310 |
Why?
|
| Mice, Nude | 11 | 2025 | 714 | 0.300 |
Why?
|
| Mice | 21 | 2025 | 18488 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 5 | 2017 | 387 | 0.290 |
Why?
|
| Piperidines | 3 | 2020 | 232 | 0.290 |
Why?
|
| Phosphoproteins | 1 | 2011 | 435 | 0.290 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2025 | 600 | 0.270 |
Why?
|
| Tongue Neoplasms | 3 | 2015 | 31 | 0.270 |
Why?
|
| Radiation Tolerance | 2 | 2025 | 60 | 0.270 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2020 | 60 | 0.270 |
Why?
|
| Animals | 28 | 2025 | 34375 | 0.250 |
Why?
|
| Carcinoma | 4 | 2013 | 283 | 0.250 |
Why?
|
| Quinazolines | 3 | 2014 | 181 | 0.250 |
Why?
|
| Prognosis | 6 | 2024 | 4952 | 0.250 |
Why?
|
| Proteomics | 1 | 2011 | 607 | 0.250 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 677 | 0.250 |
Why?
|
| Pyrazoles | 6 | 2021 | 358 | 0.250 |
Why?
|
| Keratinocytes | 2 | 2025 | 74 | 0.240 |
Why?
|
| Paraffin Embedding | 1 | 2025 | 42 | 0.230 |
Why?
|
| Formaldehyde | 1 | 2025 | 41 | 0.230 |
Why?
|
| Gain of Function Mutation | 2 | 2025 | 114 | 0.230 |
Why?
|
| Tissue Fixation | 1 | 2025 | 38 | 0.220 |
Why?
|
| Pyrimidines | 6 | 2020 | 443 | 0.220 |
Why?
|
| Chemotactic Factors | 1 | 2004 | 16 | 0.220 |
Why?
|
| Homologous Recombination | 2 | 2021 | 99 | 0.220 |
Why?
|
| Thyroid Neoplasms | 3 | 2013 | 248 | 0.210 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2025 | 93 | 0.210 |
Why?
|
| Cigarette Smoking | 1 | 2025 | 80 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1356 | 0.210 |
Why?
|
| Pyrimidinones | 6 | 2021 | 65 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 4 | 2015 | 1218 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2015 | 341 | 0.190 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 1617 | 0.190 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 31 | 0.190 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2022 | 61 | 0.190 |
Why?
|
| Nuclear Proteins | 4 | 2017 | 1226 | 0.190 |
Why?
|
| Dinoprostone | 1 | 2022 | 67 | 0.190 |
Why?
|
| Calculi | 1 | 2022 | 15 | 0.180 |
Why?
|
| Drug Synergism | 5 | 2025 | 239 | 0.180 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2014 | 200 | 0.180 |
Why?
|
| Dendritic Cells | 1 | 2004 | 438 | 0.180 |
Why?
|
| Cluster Analysis | 2 | 2014 | 418 | 0.180 |
Why?
|
| CREB-Binding Protein | 1 | 2021 | 55 | 0.180 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2021 | 50 | 0.180 |
Why?
|
| Rad51 Recombinase | 1 | 2021 | 32 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2020 | 262 | 0.170 |
Why?
|
| Histone Acetyltransferases | 1 | 2021 | 224 | 0.170 |
Why?
|
| S Phase | 2 | 2017 | 73 | 0.170 |
Why?
|
| Phosphorylation | 6 | 2017 | 1571 | 0.160 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2020 | 22 | 0.160 |
Why?
|
| Serpins | 3 | 2005 | 34 | 0.160 |
Why?
|
| Indazoles | 1 | 2020 | 35 | 0.160 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 3 | 2025 | 35 | 0.160 |
Why?
|
| Carcinogenesis | 2 | 2020 | 357 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 256 | 0.150 |
Why?
|
| Genomics | 4 | 2016 | 1625 | 0.150 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 2004 | 39 | 0.150 |
Why?
|
| Papillomaviridae | 4 | 2022 | 179 | 0.150 |
Why?
|
| DNA, Mitochondrial | 1 | 2020 | 241 | 0.140 |
Why?
|
| Blotting, Western | 5 | 2014 | 1018 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 5 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2017 | 53 | 0.130 |
Why?
|
| Databases, Genetic | 1 | 2020 | 500 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2017 | 59 | 0.130 |
Why?
|
| Baculoviridae | 4 | 2004 | 41 | 0.130 |
Why?
|
| Pteridines | 1 | 2017 | 10 | 0.130 |
Why?
|
| LIM Domain Proteins | 1 | 2017 | 67 | 0.130 |
Why?
|
| Keratosis, Actinic | 1 | 2016 | 14 | 0.120 |
Why?
|
| Precancerous Conditions | 2 | 2016 | 284 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 427 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2020 | 1521 | 0.120 |
Why?
|
| Mitosis | 2 | 2014 | 190 | 0.120 |
Why?
|
| Disease Progression | 4 | 2016 | 2206 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 174 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 1626 | 0.120 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2015 | 11 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 18 | 0.120 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2015 | 49 | 0.120 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2971 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 54 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 566 | 0.110 |
Why?
|
| Cellular Senescence | 2 | 2014 | 221 | 0.110 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2011 | 12 | 0.110 |
Why?
|
| Mitochondria | 1 | 2020 | 759 | 0.110 |
Why?
|
| Mammary Glands, Human | 1 | 2015 | 81 | 0.110 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 3 | 2021 | 8 | 0.110 |
Why?
|
| Interleukin-8 | 2 | 2005 | 207 | 0.110 |
Why?
|
| Computational Biology | 2 | 2021 | 872 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2011 | 66 | 0.100 |
Why?
|
| Subtilisins | 2 | 2004 | 11 | 0.100 |
Why?
|
| Female | 13 | 2025 | 71186 | 0.100 |
Why?
|
| Carcinoma, Papillary | 2 | 2013 | 92 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2014 | 230 | 0.100 |
Why?
|
| Caspase 8 | 1 | 2013 | 26 | 0.100 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 4696 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2022 | 115 | 0.100 |
Why?
|
| Cathepsins | 2 | 2003 | 26 | 0.100 |
Why?
|
| Glucose | 2 | 2023 | 848 | 0.100 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2012 | 2 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 106 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2013 | 92 | 0.100 |
Why?
|
| Tumor Burden | 4 | 2017 | 239 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 934 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2011 | 296 | 0.090 |
Why?
|
| Point Mutation | 1 | 2013 | 339 | 0.090 |
Why?
|
| Smoking | 2 | 2014 | 926 | 0.090 |
Why?
|
| Male | 11 | 2024 | 65267 | 0.090 |
Why?
|
| F-Box Proteins | 1 | 2011 | 32 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 204 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 4 | 2017 | 989 | 0.090 |
Why?
|
| Mucous Membrane | 1 | 2011 | 88 | 0.080 |
Why?
|
| Carrier Proteins | 3 | 2005 | 1024 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2021 | 26 | 0.080 |
Why?
|
| Diphenylamine | 1 | 2010 | 5 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2011 | 114 | 0.080 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 107 | 0.080 |
Why?
|
| Neoplasms | 2 | 2022 | 2969 | 0.080 |
Why?
|
| Phenotype | 5 | 2022 | 4516 | 0.080 |
Why?
|
| Benzamides | 1 | 2010 | 122 | 0.080 |
Why?
|
| Cell Line | 4 | 2015 | 2605 | 0.080 |
Why?
|
| Exome | 1 | 2014 | 1076 | 0.080 |
Why?
|
| Glutamine | 1 | 2011 | 202 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 1316 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1610 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1833 | 0.080 |
Why?
|
| Precision Medicine | 2 | 2023 | 376 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 364 | 0.070 |
Why?
|
| Subcellular Fractions | 2 | 2005 | 88 | 0.070 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 803 | 0.070 |
Why?
|
| Genes, p53 | 3 | 2015 | 213 | 0.070 |
Why?
|
| Pregnancy Trimester, First | 1 | 2008 | 120 | 0.070 |
Why?
|
| DNA Repair | 2 | 2021 | 562 | 0.070 |
Why?
|
| Aged | 2 | 2024 | 21261 | 0.060 |
Why?
|
| Middle Aged | 3 | 2024 | 28889 | 0.060 |
Why?
|
| Trophoblasts | 1 | 2008 | 117 | 0.060 |
Why?
|
| Disulfides | 2 | 2004 | 79 | 0.060 |
Why?
|
| Transfection | 3 | 2017 | 960 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 414 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 382 | 0.060 |
Why?
|
| DNA Replication | 2 | 2017 | 359 | 0.060 |
Why?
|
| Gene Expression | 3 | 2019 | 1502 | 0.060 |
Why?
|
| Protein Sorting Signals | 1 | 2005 | 41 | 0.060 |
Why?
|
| Smoke | 1 | 2025 | 66 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2004 | 51 | 0.050 |
Why?
|
| Adult | 2 | 2024 | 31719 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2005 | 2568 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2021 | 598 | 0.050 |
Why?
|
| Trypsin | 1 | 2004 | 81 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2990 | 0.050 |
Why?
|
| Cellular Reprogramming | 1 | 2025 | 127 | 0.050 |
Why?
|
| Cornea | 2 | 2005 | 566 | 0.050 |
Why?
|
| CpG Islands | 2 | 2015 | 338 | 0.050 |
Why?
|
| Genotype | 2 | 2022 | 2655 | 0.050 |
Why?
|
| Pancreatic Elastase | 1 | 2003 | 12 | 0.050 |
Why?
|
| Placenta | 1 | 2008 | 529 | 0.050 |
Why?
|
| Fibrinolysin | 1 | 2003 | 10 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2008 | 777 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2015 | 85 | 0.050 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 7 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2022 | 21 | 0.050 |
Why?
|
| Aurora Kinases | 1 | 2022 | 26 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 140 | 0.050 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2022 | 81 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2003 | 89 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2022 | 78 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 113 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2022 | 34 | 0.050 |
Why?
|
| Radiobiology | 1 | 2021 | 3 | 0.050 |
Why?
|
| Epigenomics | 1 | 2023 | 186 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2022 | 188 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 83 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1405 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 2022 | 157 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 181 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 3413 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2022 | 229 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 249 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2008 | 2437 | 0.040 |
Why?
|
| Serine Peptidase Inhibitor Kazal-Type 5 | 3 | 2005 | 6 | 0.040 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 3 | 2005 | 9 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2025 | 807 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 482 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2008 | 3616 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 41 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 1958 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2025 | 2363 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2022 | 752 | 0.040 |
Why?
|
| Cell Survival | 1 | 2021 | 854 | 0.040 |
Why?
|
| Kidney | 1 | 2005 | 1309 | 0.030 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 160 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 749 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 1745 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 2143 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2017 | 83 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2016 | 30 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2017 | 58 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 589 | 0.030 |
Why?
|
| Gene Editing | 1 | 2019 | 229 | 0.030 |
Why?
|
| ras Proteins | 1 | 2017 | 146 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 310 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 195 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 515 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 4769 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2005 | 2564 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 496 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 82 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 2014 | 36 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 1008 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 157 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2014 | 16 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2014 | 15 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 75 | 0.030 |
Why?
|
| Insecta | 2 | 2004 | 51 | 0.030 |
Why?
|
| Time Factors | 2 | 2017 | 6279 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 420 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 910 | 0.020 |
Why?
|
| Spodoptera | 2 | 2003 | 28 | 0.020 |
Why?
|
| Skin | 1 | 2016 | 553 | 0.020 |
Why?
|
| Dasatinib | 1 | 2013 | 53 | 0.020 |
Why?
|
| Cell Line, Transformed | 2 | 2003 | 160 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 297 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 647 | 0.020 |
Why?
|
| Karyotype | 1 | 2012 | 29 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 109 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2012 | 136 | 0.020 |
Why?
|
| Cell Shape | 1 | 2012 | 70 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 82 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1078 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 659 | 0.020 |
Why?
|
| Indoles | 1 | 2013 | 205 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 361 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2004 | 723 | 0.020 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2011 | 20 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 518 | 0.020 |
Why?
|
| Base Sequence | 2 | 2008 | 2783 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 837 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 24 | 0.020 |
Why?
|
| INDEL Mutation | 1 | 2011 | 96 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 296 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2011 | 42 | 0.020 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2011 | 20 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 122 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 141 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 164 | 0.020 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2010 | 13 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 291 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2003 | 694 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 134 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2011 | 116 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2010 | 45 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2011 | 144 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 423 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 265 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 240 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 439 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 611 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 358 | 0.020 |
Why?
|
| Metformin | 1 | 2011 | 168 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 769 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 769 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 220 | 0.020 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2008 | 4 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2010 | 246 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1163 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2008 | 126 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 2872 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 240 | 0.020 |
Why?
|
| Metabolomics | 1 | 2011 | 493 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 929 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5297 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2005 | 64 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 2151 | 0.010 |
Why?
|
| Microcirculation | 1 | 2005 | 111 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 5123 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 300 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 56 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2004 | 78 | 0.010 |
Why?
|
| Protein Denaturation | 1 | 2004 | 48 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 260 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2005 | 410 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 579 | 0.010 |
Why?
|
| Trypsin Inhibitors | 1 | 2003 | 3 | 0.010 |
Why?
|
| Cathepsin G | 1 | 2003 | 3 | 0.010 |
Why?
|
| alpha-Amylases | 1 | 2003 | 10 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2003 | 13 | 0.010 |
Why?
|
| Chymotrypsin | 1 | 2003 | 14 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2004 | 144 | 0.010 |
Why?
|
| Cathepsin K | 1 | 2003 | 2 | 0.010 |
Why?
|
| Cathepsin L | 1 | 2003 | 10 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2003 | 15 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 66 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 471 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1392 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 10959 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 297 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 436 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2003 | 191 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 609 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 199 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 442 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 881 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 773 | 0.010 |
Why?
|
| Kinetics | 1 | 2003 | 1101 | 0.010 |
Why?
|
| Lysosomes | 1 | 2003 | 260 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 1236 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 901 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 1489 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 3460 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3917 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 7572 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 12984 | 0.010 |
Why?
|